ReviewJournal of arthropod-borne diseases2021
Human Cutaneous Leishmaniosis in Iran, Up to Date-2019.
Review in Journal of arthropod-borne diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 20 citations in OpenAlex.
- Mechanistic evaluation of niosomal Rhoifolin in antileishmanial therapy and its additive potential with meglumine antimoniate.Scientific reports · 2026Article
- Molecular screening of Leishmania and Wolbachia in sand fly populations from southwestern Iran.BMC infectious diseases · 2026Article
- Article
- Nanofibrous patches for targeted therapy of cutaneous leishmaniasis caused by Leishmania major: a preclinical amphotericin B platform.Parasitology research · 2025Article
- Investigating the Effects of Demographic Factors on the Prevalence of Cutaneous Leishmaniasis in a Focus Area of Northeastern Iran.Journal of tropical medicine · 2025Article
- Predicting the Effect of Temperature Changes onTransboundary and emerging diseases · 2025Article
- Expression ofJournal of arthropod-borne diseases · 2024Article
- Article
- The Therapeutic Effect of Shirvan Herbal Ointment on Human Cutaneous Leishmaniasis Compared with Glucantime.Advanced biomedical research · 2024Article
- Predicting current and future high-risk areas for vectors and reservoirs of cutaneous leishmaniasis in Iran.Scientific reports · 2023Article
- Geographical and climatic risk factors of cutaneous leishmaniasis in the hyper-endemic focus of Bam County in southeast Iran.Frontiers in public health · 2023Article
- Molecular Detection ofJournal of arthropod-borne diseases · 2022Article
- Baseline susceptibility of a wild strain of main vectors of leishmaniasis to WHO-recommended insecticides in southeastern Iran.Parasites & vectors · 2022Article
- PCR-Based Diagnosis ofIranian journal of parasitologyArticle
- Field Efficacy of Topical Nano-Liposomal Amphotericin B (Sina Ampholeish®) Alone or in Combination with Glucantime® and Cryotherapy on Human Cutaneous Leishmaniasis.Iranian journal of parasitologyArticle
- Amphotericin B-Loaded Extracellular Vesicles Derived fromIranian journal of parasitologyArticle
- The Accuracy of Diagnosis and Genotyping ofIranian journal of parasitologyArticle
- Antileishmanial Activity of Quercetin-ZnMgFe2O4 Nanostructure onIranian journal of parasitologyArticle
- Molecular Identification of Cutaneous Leishmaniasis Species in the Northcentral Iranian Province of Alborz: Is There a New Focus on Cutaneous Leishmaniasis in the Province?Iranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous leishmaniasis is a neglected and parasitic vector borne diseases that is endemic in tropical and subtropical countries, including Iran. The aim of this study was to explain the present status of CL in Iran. This report is based on data that recorded by cutaneous leishmaniasis surveillance system in 2019, and evaluated in Center for Communicable Diseases Management in Ministry of Health in Iran. Iran has been considered an endemic area for cutaneous leishmaniasis in the world. Dependent to activities for cutaneous leishmaniasis control the number of cases decreased from 23202 in 2008 (Incidence rate 32 per 100000) to 13124 in 2019 (Incidence rate 15.8 per 100000), more cases reported from September to December, in 2019, 46% of cases had one lesion and 21% had 2 lesions, 85% of cases diagnosed when the diameter of lesions had 3 centimeters and bellows. Although the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.